Several cost-effective strategies have been proposed to optimize the identification of LS among MSI/dMMR CRC with a loss of MLH1: (1) a BRAF mutation analysis alone, (2) a MLH1 methylation analysis alone, and (3) a BRAF mutation analysis followed by a MLH1 methylation analysis in cases with no BRAF mutation. Here, BRAF is linked to colorectal carcinoma.